NCT00398983View on ClinicalTrials.gov

Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Acute Myelogenous Leukemia
Interventions
DRUG

Decitabine

20 mg/m\^2 IV over 1 hour daily for 5 days

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Eisai Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00398983 - Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML) | Biotech Hunter | Biotech Hunter